

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-18. Canceled.

19. (Currently amended) An isolated protein comprising ~~a~~ the full-length amino acid sequence of SEQ ID NO:2.

20. (Currently amended) An isolated protein having at least 90% 85% sequence identity to SEQ ID NO:2, which protein, (a) when used as an immunogen, raises antibodies which recognize full-length mesothelin (SEQ ID NO:2) or (b) is recognized by T-cells from patients with mesothelioma- or ovarian cancer-cells expressing mesothelin.

21. (Previously presented) An isolated peptide ~~comprising at least 10 amino acids, which peptide has at least 90% sequence identity to a sequence of at least 10 contiguous amino acids of~~ having 90% sequence identity over a comparison window of about 10-20 amino acid residues to mesothelin (SEQ ID NO:2), which peptide, (a) when used as an immunogen, raises antibodies which recognize full-length mesothelin (SEQ ID NO:2) or (b) is recognized by T-cells from patients with mesothelioma- or ovarian cancer- cells expressing mesothelin.

22. (Currently amended) An isolated peptide of claim 21, which peptide comprises 10 or more contiguous peptides amino acids of SEQ ID NO:2.

23. (Currently amended) A composition comprising a protein with at least 90% 85% sequence identity to mesothelin (SEQ ID NO:2), which protein, (a) when used as an immunogen, raises antibodies which recognize full-length mesothelin (SEQ ID NO:2) or (b) is recognized by T-cells from patients with mesothelioma- or ovarian cancer- cells expressing mesothelin, and a pharmaceutically acceptable carrier.

24. (Previously presented) A composition of claim 23, further comprising an adjuvant.

25. (Previously presented) A composition of claim 23, wherein said protein is conjugated to a carrier.

26. (Previously presented) A composition of claim 23, wherein the protein has the sequence of SEQ ID NO:2.

27. (Currently amended) A composition comprising a peptide an isolated peptide comprising at least 10 contiguous amino acids of mesothelin (SEQ ID NO:2, (SEQ ID NO:2), which peptide, (a) when used as an immunogen, raises antibodies which recognize full-length mesothelin (SEQ ID NO:2) or (b) is recognized by T-cells from patients with mesothelioma- or ovarian cancer- cells expressing mesothelin.

28. (Previously presented) A composition of claim 27, further comprising an adjuvant.

29. (Previously presented) A composition of claim 27, wherein said peptide is conjugated to a carrier.

30. (Currently amended) A composition comprising a peptide of at least 10 amino acids, which peptide has at least at least 90% sequence identity to a sequence of at least 10 contiguous amino acids of an isolated peptide having 90% sequence identity over a comparison window of about 10-20 amino acid residues to mesothelin (SEQ ID NO:2), wherein said peptide, (a) when used as an immunogen, raises antibodies which recognize full-length mesothelin (SEQ ID NO:2) or (b) is recognized by T-cells from patients with mesothelioma- or ovarian cancer- cells expressing mesothelin.

31. (Previously presented) A composition of claim 30, further comprising an adjuvant.

Appl. No. 09/684,599
Amdt. dated December 10, 2004
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group

PATENT
Attorney Docket No.: 015280-259120US
Client Ref. No.: E-002-1996/0

32. (Currently amended) A composition of claim 30, wherein said mesothelin-derived peptide is conjugated to a carrier.